Disease Information & Support


The Word:


Generic name Belinostat
Pronunciation beh-LIH-noh-STAT
Brand name(s), other common name(s) BeleodaqTM
Drug type  Histone deacetylase inhibitor
How the drug is given Intravenously (IV)

Belinostat is FDA approved for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). 
Side effects needing medical attention: Side effects needing medical attention: nausea, fatigue, fever, anemia, and vomiting, constipation, diarrhea, shortness of breath, rash, peripheral edema (Leg swelling caused by the fluid in leg tissues), cough, low platelet count, itching, chills, increased blood lactate dehydrogenase, decreased appetite, headache, infusion site pain, hypokalemia, prolonged QT, abdominal pain, hypotension, phlebitis, dizziness. The most common serious adverse reactions were pneumonia, fever, infection, low red blood cell count, increased creatinine, low platelet count, and multi-organ failure. 


For information on how to manage the costs of drug therapy, please see Financial Matters and Prescription Drug Coverage, or to speak with an Information Specialist, call (800) 955-4572.

last updated on Thursday, July 10, 2014